

PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002WC016604

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO : DRAWN :09/03/2023 08:03:56 RECEIVED :09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

:31 Years

AGE/SEX

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**XRAY-CHEST** 

IMPRESSION NO ABNORMALITY DETECTED

**TMT OR ECHO** 

TMT OR ECHO NEGATIVE

**ECG** 

ECG WITHIN NORMAL LIMITS WITH RAD

**MEDICAL HISTORY** 

RELEVANT PRESENT HISTORY COLD AND COUGH SINCE 1 WEEK MEDICATION TAKEN

RELEVANT PAST HISTORY OPERATED ON RIGHT EYE IN 2004

RELEVANT PERSONAL HISTORY
RELEVANT FAMILY HISTORY
HISTORY OF MEDICATIONS
HYPERTENSION
NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.80 mts
WEIGHT IN KGS. 101.2 Kgs

BMI 8 Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

**GENERAL EXAMINATION** 

MENTAL / EMOTIONAL STATE NORMAL
PHYSICAL ATTITUDE NORMAL
GENERAL APPEARANCE / NUTRITIONAL OBESE

**STATUS** 

BUILT / SKELETAL FRAMEWORK AVERAGE
FACIAL APPEARANCE NORMAL
SKIN NORMAL
UPPER LIMB NORMAL
LOWER LIMB NORMAL
NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

therke

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 1 Of 22

View Details

View Report

# PERFORMED AT:

SRL Ltd

PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA





**PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF** 

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

ACCESSION NO : 0002WC016604 PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO

AGE/SEX :31 Years :09/03/2023 08:03:56 DRAWN RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

**NORMAL** CAROTID PULSATION **NORMAL** TEMPERATURE

**PULSE** 64/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

**BRUIT** 

RESPIRATORY RATE **NORMAL** 

CARDIOVASCULAR SYSTEM

ΒP 110/80 MM HG mm/Hg

(SUPINE)

**PERICARDIUM** NORMAL APEX BEAT **NORMAL** 

**HEART SOUNDS** S1, S2 HEARD NORMALLY

**MURMURS ABSENT** 

RESPIRATORY SYSTEM

**NORMAL** SIZE AND SHAPE OF CHEST MOVEMENTS OF CHEST **SYMMETRICAL** BREATH SOUNDS INTENSITY **NORMAL** 

**BREATH SOUNDS QUALITY** VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT** 

PER ABDOMEN

**NORMAL** APPEARANCE ABSENT VENOUS PROMINENCE **NOT PALPABLE LIVER SPLEEN NOT PALPABLE** 

**ABSENT HERNIA** 

**CENTRAL NERVOUS SYSTEM** 

**NORMAL** HIGHER FUNCTIONS **NORMAL** CRANIAL NERVES CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL REFLEXES NORMAL** 

MUSCULOSKELETAL SYSTEM

**NORMAL** SPINE

Dr. J N Shukla, MBBS, AFIH **Consultant Physician** 





Page 2 Of 22

# **PERFORMED AT:**

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062

MAHARÁSHTRA, INDIA Tel: 9111591115, Fax CIN - U74899PB1995PLC045956





ACCESSION NO : 0002WC016604

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

WEST

PATIENT ID : AMANM0907910 CLIENT PATIENT ID:

WITHIN NORMAL LIMIT (6/6)

ABHA NO

AGE/SEX :31 Years Male :09/03/2023 08:03:56 DRAWN RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

NORMAL **JOINTS** 

**BASIC EYE EXAMINATION** 

CONJUNCTIVA NORMAL **EYELIDS NORMAL** EYE MOVEMENTS NORMAL **CORNEA NORMAL** 

DISTANT VISION RIGHT EYE WITHOUT

**GLASSES** 

DISTANT VISION LEFT EYE WITHOUT WITHIN NORMAL LIMIT (6/6)

**GLASSES** 

NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6) NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6) NORMAL (17/17)

COLOUR VISION

**BASIC ENT EXAMINATION** 

**NORMAL** EXTERNAL EAR CANAL TYMPANIC MEMBRANE NORMAL

NO ABNORMALITY DETECTED NOSE

**NORMAL SINUSES** 

NO ABNORMALITY DETECTED THROAT

**TONSILS NOT ENLARGED** 

**BASIC DENTAL EXAMINATION** 

TEETH NORMAL **GUMS HEALTHY** 

**SUMMARY** 

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS RAISED LYMPHOCYTES (42) RAISED TRIGLYCERIDES (201) LOW HDL CHOLESTEROL (30)

RAISED VLDL (40) RAISED SGPT (45)

RELEVANT NON PATHOLOGY DIAGNOSTICS

USG-NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS

RAISED TRIGLYCERIDES, RAISED SGPT, LOW HDL CHOLESTEROL

REDUCE PROCESSED FOODS IN DIET

OMEGA 3 FATS SUPPLEMENTS FOLLOW UP WITH PHYSICIAN

Dr. J N Shukla, MBBS, AFIH **Consultant Physician** 





Page 3 Of 22

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA



WEST

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON



PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002WC016604

PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO : DRAWN :09/03/2023 08:03:56 RECEIVED :09/03/2023 08:05:08

:31 Years

AGE/SEX

REPORTED :10/03/2023 12:36:24

Test Report Status Final Results Biological Reference Interval Units

Sterkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 4 Of 22

View Details

View Report



PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA





> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

PATIENT ID : AMANM0907910 FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08

REPORTED :10/03/2023 12:36:24

**Test Report Status** Results Units <u>Final</u>

### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

**ULTRASOUND ABDOMEN** 

**ULTRASOUND ABDOMEN** 

NO ABNORMALITIES DETECTED

Interpretation(s)
MEDICAL

WEST

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Dr. J N Shukla , MBBS, AFIH **Consultant Physician** 





Page 5 Of 22



PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







> ACCESSION NO : 0002WC016604 AGE/SEX

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

:31 Years

**Biological Reference Interval Test Report Status Final** Results Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP B	ELOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: PHOTOMETRIC MEASUREMENT	14.8	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: COULTER PRINCIPLE	5.02	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: COULTER PRINCIPLE	6.70	4.0 - 10.0	thou/μL
PLATELET COUNT  METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY	229	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)  METHOD: CALCULATED PARAMETER	44.4	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	88.4	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	29.5	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)  METHOD: CALCULATED PARAMETER	33.3	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	13.9	11.6 - 14.0	%
MENTZER INDEX	17.6		
MEAN PLATELET VOLUME (MPV)  METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM  WBC DIFFERENTIAL COUNT	10.3	6.8 - 10.9	fL
	47	4000	%
NEUTROPHILS  METHOD: VCSN TECHNOLOGY/ MICROSCOPY	47	40 - 80	90
LYMPHOCYTES  METHOD: VCSN TECHNOLOGY/ MICROSCOPY	42 High	20 - 40	%
MONOCYTES  METHOD: VCSN TECHNOLOGY/ MICROSCOPY	8	2.0 - 10.0	%
EOSINOPHILS  METHOD: VCSN TECHNOLOGY/ MICROSCOPY	3	1.0 - 6.0	%

Dr. Sushant Chikane **Consultant Pathologist** 

Dr. Reena Mittal, MD **Senior Consultant** Hematopathologist



Page 6 Of 22





PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







:09/03/2023 08:03:56

**PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

PATIENT ID : AMANM0907910

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON CLIENT PATIENT ID: WEST

RECEIVED: 09/03/2023 08:05:08 ABHA NO REPORTED :10/03/2023 12:36:24

DRAWN

	į		
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
BASOPHILS	0	0 - 1	%
METHOD: VCSN TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	3.10	2.0 - 7.0	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	2.80	1.0 - 3.0	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.54	0.2 - 1.0	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.20	0.02 - 0.50	thou/μL
METHOD: CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/μL
METHOD: CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.1		
METHOD: CALCULATED			

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Sushant Chikane Consultant Pathologist

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

Page 7 Of 22







PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







> ACCESSION NO: 0002WC016604 AGE/SEX :31 Years

> > DRAWN

PATIENT ID : AMANM0907910 FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

CLIENT PATIENT ID: ABHA NO

RECEIVED: 09/03/2023 08:05:08

REPORTED :10/03/2023 12:36:24

:09/03/2023 08:03:56

**Test Report Status** Results **Biological Reference Interval Final** Units

### **HAEMATOLOGY**

### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

### **ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD**

0 - 14mm at 1 hr E.S.R

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

### **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

### REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Sushant Chikane Consultant Pathologist

Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Page 8 Of 22





PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062

MAHARÁSHTRA, INDIA Tel: 9111591115, Fax CIN - U74899PB1995PLC045956







> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

PATIENT ID : AMANM0907910 FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08

REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

### **IMMUNOHAEMATOLOGY**

### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

### **ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

**ABO GROUP** В

METHOD: HAEMAGGLUTINATION (AUTOMATED)

**POSITIVE** RH TYPE

METHOD: HAEMAGGLUTINATION (AUTOMATED)

WEST

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist**  Page 9 Of 22





MAHARÁSHTRA, INDIA Tel: 9111591115, Fax CIN - U74899PB1995PLC045956







ACCESSION NO: 0002WC016604 AGE/SEX:31 Years Male

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

PATIENT ID : AMANM0907910

ST CLIENT PATIENT ID:
ABHA NO :

DRAWN :09/03/2023 08:03:56
RECEIVED :09/03/2023 08:05:08
REPORTED :10/03/2023 12:36:24

Test Report Status <u>Final</u> Results Biological Reference Interval Units

**BIOCHEMISTRY** 

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 94 Normal <100 mg/dL

Impaired fasting glucose:100 to

125

< 116

Diabetes mellitus: > = 126 (on

more than 1 occassion) (ADA guidelines 2021)

METHOD: SPECTROPHOTOMETRY HEXOKINASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.1

Non-diabetic Adult < 5.7 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

mg/dL

METHOD: ION-EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 99.7

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 81 Normal <140 mg/dL

Impaired glucose tolerance:140 to 199 Diabetes mellitus: > = 200 (on more than 1 occassion)

ADA guideline 2021

METHOD: SPECTROPHOTOMETRY HEXOKINASE

Comments

NOTE: PLEASE CORRELATE GLUCOSE RESULTS WITH CLINICAL & THERAPEUTIC HISTORY.

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL 154 Desirable: < 200 mg/dL

Borderline: 200 - 239

High: > / = 240

 ${\tt METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE}$ 

g. g. wadal

Dr. Sneha Wadalkar, M.D (Reg.no. MMC2012/06/1868) Junior Biochemist



Page 10 Of 22







SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA







**PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

PATIENT ID : AMANM0907910 FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

WEST

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
TRIGLYCERIDES	201 High	Normal: < 150 mg/dL Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500
METHOD: SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT W	ITH GLYCEROL BLANK	
HDL CHOLESTEROL	30 Low	At Risk: $< 40$ mg/dL Desirable: $> or = 60$
METHOD: SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT	ENZYMATIC COLORIMETRIC	
CHOLESTEROL LDL  METHOD: CALCULATED PARAMETER	84	Optimal: < 100 mg/dL Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190
NON HDL CHOLESTEROL	124	Desirable: < 130 mg/dL
NON TIDE CHOLESTEROE	124	Above Desirable: 130 -159 Borderline High: 160 - 189 High: 190 - 219 Very high: > / = 220
METHOD: CALCULATED PARAMETER		
VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER	40.0 High	< or = 30.0 mg/dL
CHOL/HDL RATIO	5.1 High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0
METHOD: CALCULATED PARAMETER		-
LDL/HDL RATIO	3.1 High	Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 - 6.0 High Risk : > 6.0

# METHOD: CALCULATED PARAMETER Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist






Page 11 Of 22



Mumbai, 400062 MAHARÁSHTRA, INDIA Tel: 9111591115, Fax CIN - U74899PB1995PLC045956





WEST

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON





Male

**REF. DOCTOR: SELF PATIENT NAME: AMAN MISHRA** 

ACCESSION NO: 0002WC016604

PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO

:09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08

:31 Years

AGE/SEX

REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units **Final** 

with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

### Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk s < or = 50 mg/dl or polyvascular disease	group or recurrent ACS (within 1 year) despite LDL-C	
Very High Risk	Established ASCVD 2. Diabetes with 2     Familial Homozygous Hypercholesterolem	major risk factors or evidence of end organ damage 3.	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk F	actors	
1. Age > or = 45 years in males and > or = 55 years in females  3. Current Cigarette smoking or tobacco use			
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals	100	Consider Drug The	rapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	$\langle OR = 30 \rangle$	$\langle OR = 60 \rangle$		
Extreme Risk Group	<OR $=$ 30	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80

. S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) **Junior Biochemist** 





Page 12 Of 22





PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062

MAHARÁSHTRA, INDIA Tel: 9111591115, Fax CIN - U74899PB1995PLC045956







> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

WEST

PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

**Test Report Status** <u>Final</u> Results

**Biological Reference Interval** Units

High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

### LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL  METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD	0.34	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.17	< or = 0.3	mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOπZ	ZATION		
BILIRUBIN, INDIRECT  METHOD: CALCULATED PARAMETER	0.17	0.0 - 0.9	mg/dL
TOTAL PROTEIN	7.0	6.0 - 8.0	g/dL
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC-BIURET, REAGEN	T BLANK, SERUM BLANK		
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DY	E BINDING		
GLOBULIN	2.5	2.0 - 3.5	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.8	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE	20	Upto 40	U/L
(AST/SGOT) METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE	ACTIVATION ( DED) IFCC		
	• •		117
ALANINE AMINOTRANSFERASE (ALT/SGPT)	45 High	Upto 41	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE	` '		
ALKALINE PHOSPHATASE	71	40 - 129	U/L
METHOD: SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	26	< 60	U/L
METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-G	LUTAMYL-CARBOXY-NITROANILIDE - 1	FCC	
LACTATE DEHYDROGENASE	214	< 232	U/L
METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	11	6 - 20	mg/dL

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) **Junior Biochemist** 

METHOD: SPECTROPHOTOMETRY, UREASE -COLORIMETRIC





Page 13 Of 22

# **PERFORMED AT:**

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

WEST

PATIENT ID : AMANM0907910

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

		<u> </u>		
Test Report Status	<u>Final</u>	Results	Biological Reference	Interval Units
CREATININE, SERUM				
-		0.83 Low	0.90 - 1.30	ma/dl
CREATININE	TTDV 1AECE'S ALVALINE DI	CRATE KINETIC - RATE BLANKED - IFCC-1		mg/dL
BUN/CREAT RATIO	INT, JAITE 3 ALKALINE FIC	CRATE RINETIC - RATE BEARRED - ITCC-	IDMS STANDANIZED	
•		13.25	8 - 15	
BUN/CREAT RATIO  METHOD: CALCULATED PARA	METER	13.25	8 - 15	
URIC ACID, SERUM	MILILIX			
URIC ACID		5.1	3.4 - 7.0	mg/dL
METHOD : SPECTROPHOTOME	TRY, ENZYMATIC COLORIM	·	3.4 - 7.0	mg/ dL
TOTAL PROTEIN, SER		2.1120 0.120.102		
TOTAL PROTEIN		7.0	6.0 - 8.0	g/dL
	ETRY, COLORIMETRIC -BIUF	RET, REAGENT BLANK, SERUM BLANK	0.0 0.0	9/ 42
ALBUMIN, SERUM	,	, , , , , , , , , , , , , , , , , , , ,		
ALBUMIN		4.5	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOME	ETRY, BROMOCRESOL GREE			3,
GLOBULIN				
GLOBULIN		2.5	2.0 - 3.5	g/dL
METHOD : CALCULATED PARA	AMETER	_		-
ELECTROLYTES (NA/I	K/CL), SERUM			
SODIUM, SERUM		140	136 - 145	mmol/L
METHOD : ISE INDIRECT				
POTASSIUM, SERUM		4.00	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT				
CHLORIDE, SERUM		103	98 - 106	mmol/L
METHOD: ISE INDIRECT				
Interpretation(s)				

Chloride

g.g.wadal

Sodium

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) **Junior Biochemist** 





Page 14 Of 22







Mumbai, 400062 MAHARÁSHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956



Potassium





ACCESSION NO: 0002WC016604

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

PATIENT ID : AMANM0907910 CLIENT PATIENT ID:

ABHA NO

:09/03/2023 08:03:56 DRAWN RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

:31 Years

AGE/SEX

**Test Report Status** Results **Biological Reference Interval Final** Units

Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

### Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin,

ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
  2. eAG gives an evaluation of blood glucose levels for the last couple of months.
  3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

### HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic

. S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) **Junior Biochemist** 





Page 15 Of 22

# **PERFORMED AT:**

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







ACCESSION NO : 0002WC016604

PATIENT ID : AMANM0907910 FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

CLIENT PATIENT ID: ABHA NO

:09/03/2023 08:03:56 DRAWN RECEIVED: 09/03/2023 08:05:08

:31 Years

AGE/SEX

REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval Final** Units

anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in
a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

CLIDE > 25% of alternate pattorni (Boroliate animity Ciroliatography) is recommended for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin
treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c
LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget'''s disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson'''s disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom'''s disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing

enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
  Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, ŚERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome

Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom"""""""""" disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver, Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) **Junior Biochemist** 





Page 16 Of 22

View Report

# **PERFORMED AT:**

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







ACCESSION NO: 0002WC016604 AGE/SEX:31 Years Male

PATIENT ID : AMANMO907910

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON
WEST

ABHA NO:

DRAWN :09/03/2023 08:03:56 RECEIVED :09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

Test Report Status <u>Final</u> Results Biological Reference Interval Units

### **CLINICAL PATH - URINALYSIS**

### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH 6.0 5.00 - 7.50 1.005 Low 1.010 - 1.030 SPECIFIC GRAVITY **PROTEIN** NOT DETECTED NOT DETECTED **GLUCOSE** NOT DETECTED NOT DETECTED **KETONES** NOT DETECTED NOT DETECTED **BLOOD** NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED UROBILINOGEN NOT DETECTED **NITRITE** NOT DETECTED NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

PUS CELL (WBC'S)

0-1

0-5

/HPF

CASTS

NOT DETECTED

NOT DETECTED

/HPF

O-5

/HPF

CASIS NOT DETECTED

CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

## Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

S. S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist





Page 17 Of 22

View Details

View Report



SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062

MAHARÁSHTRA, INDIA Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956







> ACCESSION NO : 0002WC016604 AGE/SEX :31 Years

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

WEST

PATIENT ID : AMANM0907910 CLIENT PATIENT ID:

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08

REPORTED :10/03/2023 12:36:24

**Test Report Status** <u>Final</u> Results

ABHA NO

**Biological Reference Interval** Units

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

g.g.wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 18 Of 22





PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







**PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO: 0002WC016604 AGE/SEX :31 Years

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

WEST

PATIENT ID : AMANM0907910 CLIENT PATIENT ID:

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08

REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

ABHA NO

# **CLINICAL PATH - STOOL ANALYSIS**

### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

### MICROSCOPIC EXAMINATION, STOOL

**REMARK** 

TEST CANCELLED AS SPECIMEN NOT RECEIVED

### Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc.The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

# ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist





Page 19 Of 22



SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







> ACCESSION NO: 0002WC016604 AGE/SEX :31 Years

PATIENT ID : AMANM0907910 FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

CLIENT PATIENT ID: ABHA NO

DRAWN :09/03/2023 08:03:56 RECEIVED: 09/03/2023 08:05:08

REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3.
- 4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist





Page 20 Of 22



Mumbai, 400062 MAHARÁSHTRA, INDIA Tel: 9111591115, Fax CIN - U74899PB1995PLC045956







> ACCESSION NO: 0002WC016604 AGE/SEX :31 Years

PATIENT ID : AMANM0907910

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

CLIENT PATIENT ID: ABHA NO

:09/03/2023 08:03:56 DRAWN RECEIVED: 09/03/2023 08:05:08 REPORTED :10/03/2023 12:36:24

**Test Report Status** Results **Biological Reference Interval** Units **Final** 

### **SPECIALISED CHEMISTRY - HORMONE**

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

### THYROID PANEL, SERUM

80.0 - 200.0 ng/dL T3 122.0

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

9.05 5.10 - 14.10 T4 μg/dL

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

TSH (ULTRASENSITIVE) 0.270 - 4.200μIU/mL 1.880

METHOD: SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
	100				hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
	100000000				(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) **Junior Biochemist** 





Page 21 Of 22





PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA







PATIENT NAME: AMAN MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002WC016604

FLAT NO.6, NEW RAJENDRA PARK, GOREGAON

PATIENT ID : AMANM0907910

CLIENT PATIENT ID:

DRAWN :09/03/2023 08:03:56
RECEIVED :09/03/2023 08:05:08
REPORTED :10/03/2023 12:36:24

:31 Years

AGE/SEX

Test Report Status <u>Final</u> Results Biological Reference Interval Units

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

\*\*End Of Report\*\*
Please visit www.srlworld.com for related Test Information for this accession

### **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

S. S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist





Page 22 Of 22

View Details

View Report



SKL LTG PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA

